- Home
- PEN vs BBIO Comparison
PEN vs BBIO Comparison
Compare PEN & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- BBIO
- Stock Information
- Founded
- PEN 2004
- BBIO 2015
- Country
- PEN United States
- BBIO United States
- Employees
- PEN N/A
- BBIO N/A
- Industry
- PEN Medical/Dental Instruments
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- BBIO Health Care
- Exchange
- PEN Nasdaq
- BBIO Nasdaq
- Market Cap
- PEN 9.7B
- BBIO 10.4B
- IPO Year
- PEN 2015
- BBIO 2019
- Fundamental
- Price
- PEN $231.31
- BBIO $61.41
- Analyst Decision
- PEN Strong Buy
- BBIO Strong Buy
- Analyst Count
- PEN 16
- BBIO 18
- Target Price
- PEN $307.50
- BBIO $73.89
- AVG Volume (30 Days)
- PEN 370.3K
- BBIO 2.7M
- Earning Date
- PEN 11-05-2025
- BBIO 10-29-2025
- Dividend Yield
- PEN N/A
- BBIO N/A
- EPS Growth
- PEN 916.05
- BBIO N/A
- EPS
- PEN 3.74
- BBIO N/A
- Revenue
- PEN $1,280,152,000.00
- BBIO $353,780,000.00
- Revenue This Year
- PEN $15.52
- BBIO $123.32
- Revenue Next Year
- PEN $14.20
- BBIO $73.46
- P/E Ratio
- PEN $60.50
- BBIO N/A
- Revenue Growth
- PEN 12.92
- BBIO 62.46
- 52 Week Low
- PEN $221.26
- BBIO $21.72
- 52 Week High
- PEN $310.00
- BBIO $69.48
- Technical
- Relative Strength Index (RSI)
- PEN 34.48
- BBIO 60.48
- Support Level
- PEN $221.26
- BBIO $60.79
- Resistance Level
- PEN $260.00
- BBIO $69.48
- Average True Range (ATR)
- PEN 7.60
- BBIO 2.89
- MACD
- PEN -2.31
- BBIO 0.39
- Stochastic Oscillator
- PEN 25.94
- BBIO 51.76
About PEN Penumbra Inc.
Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.